iShares MSCI EAFE Value ETF
iShares · Tracks MSCI EAFE Value Index · Inception Aug 1, 2005
Composite score
Based on a 0.31% expense ratio.
Based on $23.72B in net assets.
Top-10 holdings represent 19.7% of net assets.
International Developed base · ETF wrapper · 4.62% TTM yield.
The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.1).
Use EFV in our tools
Tool · Cost
Compare EFV's fee against another fund
Compounds the 0.31% expense ratio against a peer over decades.
Tool · Overlap
Compare EFV's holdings with peers
Pairwise holdings heatmap, pre-loaded with similar International Developed funds.
Tool · TLH
Find a tax-loss harvesting partner for EFV
Ranks every catalog fund by holdings overlap, flags wash-sale risk.
Tool · Placement
Where should this fund live across your accounts?
Asset-location optimizer — places each fund in taxable / tax-deferred / Roth.
Top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | HSBC HOLDINGS PLC | 2.77% |
| 2 | Roche Holding AG | 2.51% |
| 3 | Nestle S.A. | 2.29% |
| 4 | SHELL PLC | 2.27% |
| 5 | Mitsubishi UFJ Financial Group, Inc. | 1.77% |
| 6 | BHP GROUP LIMITED | 1.76% |
| 7 | TOTALENERGIES SE | 1.62% |
| 8 | TOYOTA MOTOR CORPORATION | 1.59% |
| 9 | Banco Santander, S.A. | 1.57% |
| 10 | Allianz SE | 1.52% |
Compare EFV with another fund
Or skim the closest-overlap funds below.
Similar ETFs by holdings overlap
Open EFV at a brokerage
Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.